Big Pharma is paying attention to Provectus and PV-10 because of data that is available publicly (and under CDA). All of the companies on the above list save two previously had been in contact with the company to varying degrees. One of the remaining two recently reached out to Provectus after the MM Phase 2 data was made final at ESMO 2012.
No comments:
Post a Comment